Arena Pharmaceuticals presents new Phase 2 data for etrasimod and olorinab

Arena Pharmaceuticals presented new Phase 2 data from its investigative drug candidates etrasimod and olorinab at the 14th Congress of European Crohn’s and Colitis Organisation. “The new data presented from the Phase 2 trial of etrasimod demonstrate that both mucosal healing and histological remission were seen in patients with moderate to severe ulcerative colitis following just 12 weeks of treatment,” said Laurent Peyrin-Biroulet, MD PhD, Professor of Medicine and Head of the Inflammatory Bowel Disease Unit, Inserm, University Hospital of Nancy, France. “These results continue to support etrasimod’s potential as an important future therapy and we look forward to further validating these data in the soon to be initiated ELEVATE Phase 3 clinical program for etrasimod in UC.”
https://thefly.com/landingPageNews.php?id=2876523